Sunday, November 29th | 13 Kislev 5781

Subscribe
November 20, 2020 10:54 am

Israel Nears Deal for AstraZeneca’s COVID-19 Vaccine

avatar by Reuters and Algemeiner Staff

AstraZeneca’s logo is reflected in a drop on a syringe needle, in this illustration, taken on Nov. 9, 2020. Photo: Reuters / Dado Ruvic / Illustration / File.

Israel has reached an understanding with AstraZeneca to receive about 10 million doses of its experimental COVID-19 vaccine, a joint statement from the Israeli government and the drugmaker said on Friday.

Details of the agreement were being finalized, the statement said, without giving an expected signing date.

An initial supply is expected to arrive in Israel in the first half of 2021, subject to approval by regulatory authorities in Europe, the United States and Israel, the statement said.

The vaccine being developed by AstraZeneca and its partner Oxford University is likely to be a two-dose course of treatment, meaning that 10 million doses would cover more than half of Israel‘s population of 9 million.

Related coverage

November 29, 2020 1:00 pm
0

Israel 2021 Budget Worth $129 Billion to Be Presented to PM Monday

Israel's Finance Ministry will present a long awaited 2021 state budget to Prime Minister Benjamin Netanyahu on Monday that will...

“This is a historic agreement led by the company’s local representation that will enable access to the vaccine for millions of Israeli citizens,” said Ohad Goldberg, chief executive of AstraZeneca Israel.

Data published on Thursday showed AstraZeneca’s vaccine candidate produced a strong immune response in older adults. Researchers are expected to release late-stage trial results by Christmas.

Israel has cast a wide net in its quest for access to a coronavirus vaccine. It has signed supply agreements with Pfizer and Moderna, and is in talks with Russia for its Sputnik V vaccine.

Israel is also developing its own vaccine that, if successful, could be ready for sale by the end of the summer.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.